Skip to content
Semaglutide
-
Dr. Reddy’s halts generic semaglutide supply due to API quality issues
The setback comes at a crucial time as competition intensifies in the fast-growing market for lower-cost versions of Novo Nordisk’s blockbuster diabetes and obesity medicine.
-
Novo Nordisk to present new Semaglutide MASH data from ESSENCE trial at EASL 2026
The company’s presentations at EASL 2026 build on results from the Phase 3 ESSENCE programme, where semaglutide 2.4 mg previously demonstrated significant reductions in liver inflammation and fibrosis among patients with MASH.